Leiner’s Return To U.S. OTC Market Complicated By FDA Warning, DOJ Inquiry

FDA's investigation into manufacturing and quality control issues at Leiner Health Products' South Carolina facility revealed a culture of mismanagement that created a pattern of undetected production errors and overlooked discrepancies regarding product development, according to the agency